Udenafil CAS 268203-93-6

Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC₅₀ of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Multas officinas summus qualitas habemus cum magna cooperatione, quae vobis praebere potest magnas qualitates productorum et pretia competitive. Etiam infringo pro mole emptionibus dare possumus. Et nos cooperamur cum multis onerariis professionalibus societatibus transmissis, fructus tuto ac blande manibus tuis tradere possumus. Partus tempus est circiter 3-20 dies post confirmationem solutionis.

Product Name:	Udenafil
Synonyms:	5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98%
CAS;	268203-93-6
MF:	C25H36N6O4S
MW:	516.66
EINECS:	251-228-4
Product Categories:	Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	268203-93-6.mol

1. esne officinam vel negotiationem societatis?
Societas industriae et mercaturae sumus integrantes, si unus-subsisto servicio.OEM accipi posset.

2. Tu exempla praebes? Estne gratis an extra?
Free samples.The sample's fee need to be paid by your side.

3. Habesne testimoniales ad quale imperium?
ISO 9001:2008 certificatio qualitatis curandae.

4. Quid providere possim sententia?
Pis nos certiores facti generis, quod opus est, quantitatem, electronicam ac peculiarem requisita. Auctoritas pro tempore referenda erit.

5. Quod genus solucionis modum vultis Quales condiciones accipiuntur?
Accepta Delivery Terms: FOB, CFR, CIF, EXW;
Acceptae Payment Currency: USD;
Type: T/T, Western Union; Coin Paypal, Trade Assurance.
Lingua Latina.